NCT07329556Not yet recruiting
Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified. This observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements. By comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 28 Dec 2025
- Start date
- 15 Jan 2026
- Primary completion date
- 15 Jan 2027
- Lead sponsor
- Bursa City Hospital
- NCT number
- NCT07329556
What you commit to
- Study type: Observational
- Planned participants: 300
- From 15 Jan 2026 to the primary completion date, 15 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of diabetes mellitus (type 1 or type 2)
- Active malignancy or history of malignancy within the past 5 years
- Presence of acute infection or acute inflammatory condition at the time of assessment
- Secondary causes of systemic inflammation unrelated to the underlying rheumatic disease (e.g., uncontrolled endocrine disorders, chronic liver disease)
- Presence of significant skin conditions (e.g., extensive dermatitis, scars, tattoos, or burns) at the measurement site that may interfere with skin autofluorescence assessment
Lab values
- Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m²
Age
- Use of medications known to markedly affect AGE accumulation or skin autofluorescence measurements (e.g., recent high-dose systemic glucocorticoids)
Other
- Pregnancy or breastfeeding
- Inability to comply with study procedures or to provide informed consent
Who the study is looking for
- Age between 18 and 75 years
- Diagnosis of an inflammatory rheumatic disease (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, connective tissue diseases, Behçet disease, familial Mediterranean fever, or crystal arthropathies), confirmed by a rheumatologist
- Healthy volunteers without a history of rheumatic or chronic inflammatory disease (for the control group)
- Ability to undergo non-invasive skin autofluorescence measurement
- Ability and willingness to provide written informed consent
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.